Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer-Reference-Cited by-同舟云学术

Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer

Published:2019-03-29 Issue:2 Volume:273 Page:341-349
ISSN:0003-4932
Container-title:Annals of Surgery
language:en
Short-container-title:

Author:

Truty Mark J.,Kendrick Michael L.,Nagorney David M.,Smoot Rory L.,Cleary Sean P.,Graham Rondell P.,Goenka Ajit H.,Hallemeier Christopher L.,Haddock Michel G.,Harmsen William S.,Mahipal Amit,McWilliams Robert R.,Halfdanarson Thorvardur R.,Grothey Axel F.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Surgery

Reference50 articles.

1. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study;Saad;BMC Cancer,2018

2. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011

3. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Von Hoff;N Engl J Med,2013

4. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

5. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer;Kharofa;Radiother Oncol,2014

Cited by 319 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Locally Advanced Pancreas Cancer, Is There a Role for Surgery?;Surgical Clinics of North America;2024-10

2. A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable and borderline resectable pancreatic cancer;Surgery;2024-10

3. Impact of proton pump inhibitors on pathologic response rates following fluoropyrimidine‐based neoadjuvant chemotherapy in pancreatic cancer patients;Journal of Surgical Oncology;2024-09-11

4. Financial Toxicity of Long‐Term Survivors Who Underwent Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma;Journal of Surgical Oncology;2024-09-05

5. The Relationship between Treatment Response and Overall Survival in Borderline, Non-Resectable and Resectable Pancreatic Cancer Patients Treated with Neoadjuvant FOLFIRINOX;Journal of Clinical Medicine;2024-09-02